SynthesisJournal of gastroenterology2011
Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review.
Synthesis in Journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 3 syntheses or guidelines pooled it, 199 citations in OpenAlex.
- Endometriosis and irritable bowel syndrome: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2021Pooled it
- Association between Helicobacter pylori infection and irritable bowel syndrome: A systematic review and meta-analysis.Medicine · 2020Pooled it
- Evidence-based clinical practice guidelines for irritable bowel syndrome.Journal of gastroenterology · 2015Guideline
- Changes in Digestive Health, Satiety and Overall Well-Being after 14 Days of a Multi-Functional GI Primer Supplement.Nutrients · 2024Trial
- Budesonide as induction therapy for incomplete microscopic colitis: A randomised, placebo-controlled multicentre trial.United European gastroenterology journal · 2021Trial
- Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation.JCI insight · 2021Trial
- The Effects on Immune Function and Digestive Health of Consuming the Skin and Flesh of ZespriNutrients · 2020Trial
- Low-FODMAPWorld journal of gastroenterology · 2018Trial
- A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms.Digestive diseases and sciences · 2016Trial
- Possible etiology of improvements in both quality of life and overlapping gastroesophageal reflux disease by proton pump inhibitor treatment in a prospective randomized controlled trial.BMC gastroenterology · 2013Trial
- Study on the therapeutic effects of the primary active ingredients in cinnamon oil for constipation-predominant irritable bowel syndrome and their regulatory effects on the 5-HT signaling pathway and gut microbiota.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Low-Grade Inflammation: Pathophysiological Mechanisms and Drug Targets in Irritable Bowel Syndrome with Diarrhea.Journal of inflammation research · 2026Review
- Why are disorders of gut-brain interaction (DGBI) often food-related? Duodenal eosinophils and mast cells, small intestinal bacteria, food allergy and altered food intake in functional dyspepsia and the irritable bowel syndrome: a new paradigm.Journal of gastroenterology · 2025Review
- Irritable Bowel Syndrome in Inflammatory Bowel Disease Patients: Prevalence, Etiology, and Treatment.Gastroenterology & hepatology · 2025Article
- A Synbiotic Combining Chitin-Glucan andInternational journal of molecular sciences · 2024Article
- Chitin-glucan improves important pathophysiological features of irritable bowel syndrome.World journal of gastroenterology · 2024Article
- Research Progress for Probiotics Regulating Intestinal Flora to Improve Functional Dyspepsia: A Review.Foods (Basel, Switzerland) · 2024Review
- Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders.Bioelectronic medicine · 2023Review
- Association between frailty and chronic constipation and chronic diarrhea among American older adults: National Health and Nutrition Examination Survey.BMC geriatrics · 2023Article
- Microbiota in Irritable Bowel Syndrome and Endometriosis: Birds of a Feather Flock Together-A Review.Microorganisms · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe causes of irritable bowel syndrome (IBS) remain obscure. Some investigators have proposed chronic low-grade mucosal inflammation as a potential etiological factor. We performed a systematic review to examine this issue in detail.
methodsMEDLINE, EMBASE, and EMBASE classic were searched up to December 2010 to identify studies of case-control design applying tests for low-grade inflammation to either full-thickness intestinal or endoscopic mucosal biopsies from patients with IBS. Controls were required to be healthy individuals, or asymptomatic patients undergoing investigation for reasons other than the reporting of upper or lower gastrointestinal symptoms. Individual study results were summarized descriptively.
resultsThe literature search identified 1388 citations, of which 16 studies were eligible for inclusion. Individual study results were diverse, partly as a consequence of the different surrogate markers for inflammatory mechanisms studied. Mast cells, T lymphocytes, B lymphocytes, and mucosal cytokine production all appeared altered among cases with IBS in individual studies, while no study demonstrated a significant difference in numbers of plasma cells, neutrophils, or eosinophils. Some studies suggested a relationship between mast cell abnormalities and symptom severity and frequency, as well as co-existent fatigue and depression. Studies were limited by the lack of comparability of controls, and the fact that most were conducted in highly selected groups of patients with IBS.
conclusionsLow-grade mucosal inflammation, particularly mast cell activation, may be a contributory factor in the pathogenesis of IBS. Mast cell stabilizers warrant further assessment as a potential therapy in the condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.